Atom | Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

Due Dates: September 15, 2026

Funding Amounts: €7,000,000–€8,000,000 per project; 3 grants expected; single-stage application

Summary: Funds pragmatic, investigator-initiated clinical trials to optimize immunotherapeutic interventions for refractory cancer patients in Europe, focusing on real-world effectiveness and patient quality of life.

Key Information: Proposals must be academic, randomized (or cluster-randomized), and investigator-initiated, with strong end-user engagement and multidisciplinary collaboration.

Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers - European Commission

Sign in to see full grant listing